September 14, 2020 -- Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.
Neogene was founded in 2018 to advance the development of neoantigen T-cell therapies. Now, its proprietary platform allows for the isolation of neoantigen specific T-cell receptor (TCR) genes from tumor biopsies.
Tumor-infiltrating lymphocytes obtained from tumor biopsies express TCR specific for the mutated proteins found in cancer cells (neoantigens). Using DNA sequencing, DNA synthesis, and genetic screening tools, the company can identify neoantigen specific T-cell receptor genes that are subsequently engineered into personalized T cells to be used in T-cell therapies.
Initial seed funding in 2019 enabled Neogene to achieve proof of concept for its neoantigen technology platform. With the new financing, the company intends to further develop its technology with growing offices in Amsterdam and the U.S. with the goal to initiate phase I clinical studies in 2022.